ArticleTransfusion2025
Implementation of a novel hybrid cord blood banking model within a private-public-partnership.
Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Implementation of a novel hybrid cord blood banking model within a private-public-partnership.Transfusion · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUmbilical cord blood (UCB) stem cells can be collected at birth, cryopreserved, and used for transplantation in hematopoietic diseases. Typically, these stem cells are stored in public banks for allogeneic use or in private depositories for potential future utilization by the family. A proposed third option, hybrid cord blood banking, combines elements of both public and private storage. This method allows family-directed UCB to be HLA typed and included in the international registry, making it accessible to compatible patients globally. STUDY DESIGN AND
methodsWe describe the implementation of a novel hybrid cord blood banking model within a private-public partnership involving a university obstetric department, a national stem cell registry, and a private cord blood bank.
resultsFrom 2020 to 2023, 67 UCB units were collected for hybrid banking. Of these, 25 samples (37.3%) met the threshold of 120 grams for public banking. Before processing, 5 samples (7.5%) contained over 1.5 E9 total nucleated cells (TNC); after processing, 15 samples (22.46%) exceeded 1.0 E9 TNC. The viability margin of 85% was surpassed in 42 samples (62.7%). Cytofluorimetric analysis showed 36 samples (53.7%) had over 1.25 E6 CD34+ cells, with 63 samples (94.0%) exceeding 85% viability. For HLA typing and registry entry, 10 samples (14.9%) qualified for hybrid purposes, with one sample deemed unsuitable for processing. DISCUSSION: This study demonstrates the feasibility of the hybrid cord blood banking model within a private-public partnership. This new concept offers an extended option for parents to bank their child's cord blood stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.